ORIC Pharmaceuticals, Inc.
General ticker "ORIC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $672.8M (TTM average)
ORIC Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 56.7%.
Estimated limits based on current volatility of 3.4%: low 10.65$, high 11.39$
Factors to consider:
- Total employees count: 115 as of 2024
- Top business risk factors: Operational and conduct risks, Economic downturns and volatility, Dependence on product success, Regulatory and compliance, Labor/talent shortage/retention
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.57$, 10.81$]
- 2025-12-31 to 2026-12-31 estimated range: [3.85$, 9.26$]
Financial Metrics affecting the ORIC estimates:
- Negative: with PPE of -4.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.94 <= 0.33
- Positive: Shareholder equity ratio, % of 88.68 > 63.39
- Positive: Investing cash flow per share per price, % of 3.92 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term ORIC quotes
Long-term ORIC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $91.77MM | $110.78MM | $142.90MM |
| Operating Income | $-91.77MM | $-110.78MM | $-142.90MM |
| Non-Operating Income | $2.65MM | $10.08MM | $15.05MM |
| R&D Expense | $66.68MM | $85.17MM | $114.07MM |
| Income(Loss) | $-89.12MM | $-100.70MM | $-127.85MM |
| Profit(Loss)* | $-89.12MM | $-100.70MM | $-127.85MM |
| Stockholders Equity | $222.35MM | $224.09MM | $243.12MM |
| Assets | $247.18MM | $252.01MM | $274.14MM |
| Operating Cash Flow | $-75.14MM | $-85.69MM | $-112.66MM |
| Capital expenditure | $2.08MM | $0.85MM | $1.19MM |
| Investing Cash Flow | $-109.25MM | $-43.40MM | $22.14MM |
| Financing Cash Flow | $25.23MM | $85.66MM | $126.55MM |
| Earnings Per Share** | $-2.25 | $-1.96 | $-1.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.